Olimel N12e

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredients in Olimel N12e, constitute an amino acid solution presented as a 12% w/v solution for injection for intravenous use. It supplies essential and non‑essential amino acids to patients who require parenteral nutrition because they cannot receive enteral feeding or are in a catabolic state.

GNH USA supplies Olimel N12e as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and clinics worldwide, including major academic and private health systems.

Olimel N12e is employed in parenteral nutrition to provide a balanced amino acid profile for patients who cannot receive enteral feeding or who are in a catabolic state.

- Parenteral nutrition for patients unable to receive enteral feeding: delivers essential and non‑essential amino acids to meet protein and nitrogen requirements. - Critical care and postoperative patients requiring amino acid supplementation: supports tissue repair and prevents muscle loss during intensive care. - Support of protein synthesis in catabolic states: helps maintain lean body mass and immune function during illness or injury.

Intravenous administration of amino acid solutions may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients. - Electrolyte disturbances: shifts in potassium, sodium, or calcium concentrations. - Infusion site reactions: erythema, pain, or phlebitis at the catheter site. - Nausea or vomiting: gastrointestinal discomfort during or after infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention. - Severe hyperammonemia: excessive ammonia accumulation leading to neurologic symptoms. - Hepatic dysfunction: liver enzyme elevations indicating possible liver stress. - Renal impairment: worsening kidney function due to nitrogen load.

When using Olimel N12e, clinicians should observe several safety considerations to minimize risks.

- Monitor blood glucose: adjust insulin therapy as needed during infusion. - Assess electrolyte levels: regularly check serum potassium, sodium, and calcium. - Evaluate renal function: avoid or limit use in patients with severe renal insufficiency. - Screen for inborn errors of metabolism: contraindicated in phenylketonuria, maple‑sweet urine disease, or other amino‑acid disorders. - Use aseptic technique: ensure sterile handling to prevent catheter‑related infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amino acid solutions can interact with other therapies, influencing metabolic balance or increasing adverse event risk.

Major Interactions (Avoid): - Inborn errors of amino‑acid metabolism (e.g., phenylketonuria, maple‑sweet urine disease): risk of toxic metabolite accumulation. - Severe renal failure: excessive nitrogen load may worsen uremia. - High‑protein enteral nutrition administered concurrently: may cause nitrogen overload.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemic agents: may require dose adjustment due to glucose changes. - Electrolyte‑containing IV fluids: monitor for additive electrolyte shifts. - Loop diuretics: watch for volume depletion and electrolyte imbalance.